LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity

Figure 8 LGALS1 diminishes the cisplatin sensitivity of esophageal squamous cell carcinoma CDX model. A: Experimental protocol for subcutaneous tumor formation and dosing experiments in mice; B: Mice and individual tumors after different treatment approaches; C: Statistical plots of tumor weights in mice following diverse treatments; D: Growth curves of mice following various treatments; E: The LGALS1, Ki67, and BAX and vimentin protein were detected in tumor sections by multiplex immunohistochemistry staining. ^bP < 0.01, NS: Not significant.